Physician profile
Eileen M Barto
NPI 1992777890
$1,251.05
in general payments reported to CMS, 2019-2025
24 companies · $22.38 in 2025
The $22.38 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $391 · 2021: $470 · 2022: $39.74 · 2023: $0.79 · 2025: $22.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.38 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.38 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $253.44 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.58 | 2020-2022 | |
| Amgen INC. | $123.73 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $115.56 | 2019-2021 | |
| Pfizer INC. | $111.31 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $90.94 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $59.65 | 2019-2020 | |
| Amarin Pharma, INC. | $49.40 | 2020-2021 | |
| Lilly USA, LLC | $40.55 | 2020-2021 | |
| Astellas Pharma US INC | $30.44 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.11 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $26.03 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $25.14 | 2019-2020 | |
| Abbott Laboratories | $22.38 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.24 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $14.76 | 2021 | |
| Eisai INC. | $14.40 | 2020 | |
| Acadia Pharmaceuticals INC | $14.07 | 2020 | |
| Genentech USA, INC. | $14.04 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.31 | 2021 | |
| Esperion Therapeutics, INC. | $11.96 | 2021 | |
| Mylan Specialty L.P. | $11.82 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.40 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Barto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.